Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLOD2 | O00469 | 3/20 | 0.70 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.62 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.62 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.56 |
| ▸ | FEN1 | P39748 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22804709 | 0.90 | PLOD2 (0.58) | PLOD2PLOD3PLOD1ERCC5FEN1 | |
| SCHEMBL6352781 | 0.87 | ERCC5 (0.55) | PLOD2PLOD3PLOD1ERCC5FEN1 | |
| SCHEMBL8643565 | 0.85 | ERCC5 (0.53) | PLOD2PLOD3PLOD1ERCC5FEN1 | |
| SCHEMBL6526778 | 0.85 | PLOD2 (0.53) | PLOD2PLOD3PLOD1ERCC5FEN1 | |
| SCHEMBL22804864 | 0.84 | NR4A2 (0.61) | PLOD2ALDH1A1MAPTL3MBTL1LMNA | |
| SCHEMBL1095373 | 0.82 | PLOD2 (0.72) | PLOD2PLOD3PLOD1ALDH1A1MAPT | |
| SCHEMBL711849 | 0.82 | PLOD2 (1.00) | PLOD2PLOD3PLOD1MAPTLMNA | |
| SCHEMBL6344726 | 0.82 | ERCC5 (0.50) | PLOD2PLOD3PLOD1ERCC5FEN1 | |
| SCHEMBL1924889 | 0.81 | PLOD2 (0.60) | PLOD2PLOD3PLOD1ALDH1A1MAPT | |
| SCHEMBL600674 | 0.81 | ERCC5 (0.72) | ERCC5FEN1GSK3BALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087561-A1 | RETARDING AGENT IN ISOCYANATE COMPONENT OF POLYURETHANE/UREA CEMENTITIOUS HYBRID SYSTEMS | SIKA TECHNOLOGY AG (CH) | 2026-04-30 | — | — | WO | claimed |
| EP-4733284-A1 | RETARDING AGENT IN ISOCYANATE COMPONENT OF POLYURETHANE/UREA CEMENTITIOUS HYBRID SYSTEMS | Sika Technology AG (CH) | 2026-04-29 | — | — | EP | claimed |
| EP-3917908-B1 | A CONTINUOUS FLOW MICRO-TOTAL PROCESS SYSTEM FOR PREPARATION OF CELECOXIB AND ANALOGS THEREOF | COUNCIL SCIENT IND RES (IN) | 2024-08-14 | — | — | EP | claimed |
| US-11802112-B2 | Continuous flow micro-total process system for preparation of celecoxib and analogs thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-10-31 | — | — | US | claimed |
| EP-4063422-A1 | 1,3-DICARBONYL COMPOUNDS AS RETARDING ADDITIVES FOR UCRETE SYSTEMS | Construction Research & Technology GmbH (DE) | 2022-09-28 | — | — | EP | claimed |
| US-20220127235-A1 | A CONTINUOUS FLOW MICRO-TOTAL PROCESS SYTEM FOR PREPARATION OF CELCOXIB AND ANALOGS THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-04-28 | — | — | US | claimed |
| EP-3917908-A1 | A CONTINUOUS FLOW MICRO-TOTAL PROCESS SYSTEM FOR PREPARATION OF CELECOXIB AND ANALOGS THEREOF | Council of Scientific & Industrial Research (IN) | 2021-12-08 | — | — | EP | claimed |
| WO-2020157771-A1 | A CONTINUOUS FLOW MICRO-TOTAL PROCESS SYSTEM FOR PREPARATION OF CELECOXIB AND ANALOGS THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2020-08-06 | — | — | WO | claimed |
| US-6586603-B1 | Forming 4-(5-(4-chlorophenyl)-3-trifluoromethyl)-1H-pyrazol-1 -yl)benzenesulfonamide used as antiinflammatory agents; side effect reduction | G.D. SEARLE & CO. | 2003-07-01 | — | — | US | claimed |
| WO-2026087561-A1 | RETARDING AGENT IN ISOCYANATE COMPONENT OF POLYURETHANE/UREA CEMENTITIOUS HYBRID SYSTEMS | SIKA TECHNOLOGY AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4733284-A1 | RETARDING AGENT IN ISOCYANATE COMPONENT OF POLYURETHANE/UREA CEMENTITIOUS HYBRID SYSTEMS | Sika Technology AG (CH) | 2026-04-29 | — | — | EP | disclosed |
| EP-3954685-B1 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | US HEALTH (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12365653-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240368087-A1 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-11-07 | — | — | US | disclosed |
| US-5516907-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1996-05-14 | — | — | US | disclosed |
| US-5510496-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1996-04-23 | — | — | US | disclosed |
| US-5508426-A | ANTIARTHRITIC AGENT | G. D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5504215-A | Substituted pyrazolyl benzenesulfonamide compounds for the treatment of inflammation | G. D. SEARLE & CO. (US) | 1996-04-02 | — | — | US | disclosed |
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | disclosed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802112-B2 | Continuous flow micro-total process system for preparation of celecoxib and analogs thereof | PTGES2, PTGS2, CYP2J2 | PLOD2 3454/4885PLOD3 4085/4885PLOD1 4033/4885 |
| US-12365653-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | LDHB, LDHA, PDHA1 | PLOD2 2199/4885PLOD3 3125/4885PLOD1 1136/4885 |
| US-20240368087-A1 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | LDHB, LDHA, PDHA1 | PLOD2 2199/4885PLOD3 3125/4885PLOD1 1136/4885 |
| US-20220127235-A1 | A CONTINUOUS FLOW MICRO-TOTAL PROCESS SYTEM FOR PREPARATION OF CELCOXIB AND ANALOGS THEREOF | PTGES2, PTGS2, P2RX2 | PLOD2 2433/4885PLOD3 3324/4885PLOD1 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.